MIRM expecting something bigThis stock was a pendulum pick (as in from dowsing) from around August. I posted an idea at the time, and it's gone up, but been consolidating. Last week or so, I decided to let my dowsing choose a stock from the fi viz screener from ALL exchanges.
There were over 9500 stock tickers & you know whic
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−38.63 MXN
−1.83 B MXN
7.02 B MXN
39.12 M
About Mirum Pharmaceuticals, Inc.
Sector
Industry
CEO
Christopher Peetz
Website
Headquarters
Foster City
Founded
2018
FIGI
BBG0121CJQL5
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
No news here
Looks like there's nothing to report right now
MIRM buy the dip pendulum pickMy psychic friend (whom I've mentioned in other ideas) suggested I look to a pharma stock, so I put in all of healthcare of optionable stocks on a screener & this is the stock my dowsing chose.
The message is that it's going to have some kinda dump. Maybe a downgrade or something that sends it possi
NLong

Mirum Pharmaceuticals (MIRM) AnalysisAdvancements in Rare Disease Therapies:
Mirum Pharmaceuticals NASDAQ:MIRM is advancing in the biopharma sector with a focus on therapies for rare diseases. Recently, Mirum submitted a New Drug Application (NDA) for chenodiol tablets to treat cerebrotendinous xanthomatosis (CTX), following positive
NLong

$MIRM september accumulation 👁🗨*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Mirum Phar
NLong

$MIRM bear proof 👁🗨
*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management
My team e
NLong

$MIRM sniper edition #2*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Recap: My
NLong

$MIRM november update*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Recap: My
NLong

$MIRM empire strikes back*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
If you tak
NLong

$MIRM doubling down*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Recap: My
NLong

$MIRM June Update*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Mirum Pharm
NLong

See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
MIRM5806400
Mirum Pharmaceuticals, Inc. 4.0% 01-MAY-2029Yield to maturity
−5.12%
Maturity date
May 1, 2029
See all MIRM bonds
Frequently Asked Questions
The current price of MIRM is 902.37 MXN — it has increased by 14.49% in the past 24 hours. Watch MIRUM PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange MIRUM PHARMACEUTICALS INC stocks are traded under the ticker MIRM.
We've gathered analysts' opinions on MIRUM PHARMACEUTICALS INC future price: according to them, MIRM price has a max estimate of 1,477.67 MXN and a min estimate of 1,058.33 MXN. Watch MIRM chart and read a more detailed MIRUM PHARMACEUTICALS INC stock forecast: see what analysts think of MIRUM PHARMACEUTICALS INC and suggest that you do with its stocks.
MIRM reached its all-time high on Dec 10, 2024 with the price of 902.37 MXN, and its all-time low was 282.55 MXN and was reached on Aug 19, 2021. View more price dynamics on MIRM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MIRM stock is 12.65% volatile and has beta coefficient of 0.69. Track MIRUM PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is MIRUM PHARMACEUTICALS INC there?
Today MIRUM PHARMACEUTICALS INC has the market capitalization of 38.13 B, it has decreased by −5.33% over the last week.
Yes, you can track MIRUM PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
MIRUM PHARMACEUTICALS INC is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
MIRM earnings for the last quarter are −10.22 MXN per share, whereas the estimation was −5.39 MXN resulting in a −89.59% surprise. The estimated earnings for the next quarter are −6.76 MXN per share. See more details about MIRUM PHARMACEUTICALS INC earnings.
MIRUM PHARMACEUTICALS INC revenue for the last quarter amounts to 2.07 B MXN, despite the estimated figure of 2.01 B MXN. In the next quarter, revenue is expected to reach 2.02 B MXN.
MIRM net income for the last quarter is −496.01 M MXN, while the quarter before that showed −280.48 M MXN of net income which accounts for −76.84% change. Track more MIRUM PHARMACEUTICALS INC financial stats to get the full picture.
No, MIRM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 16, 2025, the company has 322 employees. See our rating of the largest employees — is MIRUM PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MIRUM PHARMACEUTICALS INC EBITDA is −1.33 B MXN, and current EBITDA margin is −18.99%. See more stats in MIRUM PHARMACEUTICALS INC financial statements.
Like other stocks, MIRM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MIRUM PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MIRUM PHARMACEUTICALS INC technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MIRUM PHARMACEUTICALS INC stock shows the strong buy signal. See more of MIRUM PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.